Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 5,080 Cr.
- Current Price ₹ 888
- High / Low ₹ 1,260 / 568
- Stock P/E 39.6
- Book Value ₹ 168
- Dividend Yield 0.00 %
- ROCE 14.6 %
- ROE 14.3 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.7% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
356 | 373 | 411 | 801 | 926 | 1,081 | 1,244 | |
315 | 322 | 356 | 704 | 813 | 927 | 1,057 | |
Operating Profit | 41 | 51 | 54 | 96 | 114 | 154 | 186 |
OPM % | 11% | 14% | 13% | 12% | 12% | 14% | 15% |
0 | 1 | 1 | 3 | 9 | 12 | 12 | |
Interest | 6 | 5 | 4 | 6 | 20 | 21 | 2 |
Depreciation | 11 | 10 | 6 | 8 | 11 | 16 | 25 |
Profit before tax | 25 | 38 | 46 | 86 | 92 | 130 | 171 |
Tax % | 20% | 26% | 26% | 25% | 26% | 27% | 25% |
20 | 28 | 34 | 64 | 68 | 94 | 128 | |
EPS in Rs | 165.67 | 232.42 | 287.50 | 532.92 | 14.16 | 16.49 | 22.41 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 16% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | 26% |
TTM: | 36% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 17% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 48 | 57 | 57 |
Reserves | 70 | 98 | 133 | 197 | 229 | 774 | 902 |
72 | 54 | 46 | 199 | 237 | 245 | 338 | |
68 | 81 | 179 | 167 | 191 | 240 | 271 | |
Total Liabilities | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 |
78 | 73 | 79 | 183 | 183 | 358 | 830 | |
CWIP | 0 | 0 | 7 | 0 | 22 | 341 | 23 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
144 | 172 | 283 | 392 | 500 | 617 | 716 | |
Total Assets | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
19 | 31 | 42 | 59 | 67 | 146 | 64 | |
-9 | -6 | -20 | -188 | -91 | -499 | -152 | |
-9 | -23 | -19 | 125 | 27 | 361 | 92 | |
Net Cash Flow | 1 | 1 | 3 | -5 | 3 | 8 | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 93 | 85 | 123 | 97 | 104 | 97 | 97 |
Inventory Days | 50 | 84 | 107 | 76 | 77 | 91 | 119 |
Days Payable | 80 | 92 | 132 | 86 | 105 | 113 | 115 |
Cash Conversion Cycle | 64 | 77 | 99 | 87 | 77 | 75 | 101 |
Working Capital Days | 30 | 45 | 39 | 37 | 58 | 77 | 81 |
ROCE % | 26% | 28% | 31% | 24% | 19% | 15% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 2d
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
31 Jul - Scheduled analyst meeting on 8 Aug 2025 to discuss Q1 FY26 unaudited financial results.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 31 Jul
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR) Regulations, 2015 For Consideration Of Unaudited (Standalone
And Consolidated) Financial Results For The Quarter Ended 30Th June, 2025.
30 Jul - Board meeting on 7 Aug 2025 to approve Q1 FY26 unaudited financial results.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
25 Jul - CRISIL monitoring report confirms full utilization of Rs 2,942 mn IPO proceeds by Innova Captab as per stated objects.
Concalls
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain